Groupama Asset Managment Increases Stake in Alnylam Pharmaceuticals, Inc. $ALNY

Groupama Asset Managment lifted its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 160.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,032,082 shares of the biopharmaceutical company’s stock after acquiring an additional 2,483,697 shares during the quarter. Groupama Asset Managment’s holdings in Alnylam Pharmaceuticals were worth $18,610,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the business. BlueCrest Capital Management Ltd purchased a new position in Alnylam Pharmaceuticals in the third quarter worth $561,000. CIBC Bancorp USA Inc. acquired a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at approximately $2,132,000. Ariadne Wealth Management LP boosted its position in Alnylam Pharmaceuticals by 38.9% during the third quarter. Ariadne Wealth Management LP now owns 703 shares of the biopharmaceutical company’s stock worth $319,000 after purchasing an additional 197 shares in the last quarter. First Affirmative Financial Network acquired a new position in shares of Alnylam Pharmaceuticals during the 3rd quarter worth $247,000. Finally, Caerus Investment Advisors LLC purchased a new stake in shares of Alnylam Pharmaceuticals in the third quarter valued at about $762,000. 92.97% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on ALNY shares. Raymond James Financial restated an “outperform” rating and issued a $472.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Monday, January 12th. Canaccord Genuity Group raised their target price on shares of Alnylam Pharmaceuticals from $415.00 to $429.00 and gave the stock a “buy” rating in a research report on Tuesday, February 17th. HC Wainwright reiterated a “buy” rating and issued a $510.00 target price on shares of Alnylam Pharmaceuticals in a report on Wednesday, February 18th. Stifel Nicolaus lifted their price objective on Alnylam Pharmaceuticals from $495.00 to $508.00 and gave the company a “buy” rating in a research note on Thursday, December 11th. Finally, Wall Street Zen cut shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 14th. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, Alnylam Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $468.84.

Alnylam Pharmaceuticals Stock Performance

Alnylam Pharmaceuticals stock opened at $314.80 on Thursday. Alnylam Pharmaceuticals, Inc. has a 52 week low of $205.87 and a 52 week high of $495.55. The company has a current ratio of 2.76, a quick ratio of 2.71 and a debt-to-equity ratio of 1.28. The stock has a market cap of $41.75 billion, a P/E ratio of 184.09 and a beta of 0.36. The stock has a 50 day moving average of $338.90 and a 200-day moving average of $406.96.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, February 12th. The biopharmaceutical company reported $1.25 EPS for the quarter, missing the consensus estimate of $1.43 by ($0.18). Alnylam Pharmaceuticals had a return on equity of 69.02% and a net margin of 6.43%.The company had revenue of $1.10 billion for the quarter, compared to the consensus estimate of $1.16 billion. During the same period in the previous year, the business posted ($0.65) EPS. The business’s revenue for the quarter was up 84.9% on a year-over-year basis. On average, analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other news, CEO Yvonne Greenstreet sold 6,799 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $327.65, for a total transaction of $2,227,692.35. Following the completion of the transaction, the chief executive officer directly owned 98,628 shares of the company’s stock, valued at approximately $32,315,464.20. This represents a 6.45% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Kevin Joseph Fitzgerald sold 1,652 shares of the stock in a transaction on Tuesday, March 3rd. The stock was sold at an average price of $319.73, for a total value of $528,193.96. Following the completion of the sale, the executive vice president directly owned 21,860 shares in the company, valued at $6,989,297.80. This represents a 7.03% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 53,923 shares of company stock worth $18,072,087. 1.50% of the stock is owned by company insiders.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.